SCHEMBL535034

SCHEMBL535034

[CH]=CCCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5184371 0.90
SCHEMBL15537018 0.87 DNM1 (0.50)
SCHEMBL9272522 0.87 DNM1 (0.50)
SCHEMBL5184695 0.77
SCHEMBL3498191 0.76
SCHEMBL3499333 0.76
SCHEMBL1541496 0.72
SCHEMBL864699 0.71
SCHEMBL5052172 0.69 NFKB1 (0.46)
SCHEMBL5052175 0.69 NFKB1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 EP claimed
WO-2023137297-A2 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROLE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-07-20 WO claimed
WO-2023004376-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-01-26 WO claimed
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 EP disclosed
WO-2024086194-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER Suvalent Therapeutics, Inc. (US) 2024-04-25 WO disclosed
WO-2023137297-A2 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROLE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-07-20 WO disclosed
WO-2023004376-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-01-26 WO disclosed
CN-114672027-B High-mechanical-strength self-repairing self-adhesive polysiloxane elastomer and preparation method thereof 杭州师范大学(CN) 2023-01-13 CN disclosed
US-10174132-B2 Heparan sulfate synthesis UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2019-01-08 US disclosed
US-9938312-B2 Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2018-04-10 US disclosed
US-20160060365-A1 HEPARAN SULFATE SYNTHESIS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2016-03-03 US disclosed
EP-2004668-B1 AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA TAU IND FARMACEUTI (IT) 2013-03-13 EP disclosed
WO-2012135049-A1 COMPOUNDS AND METHODS FOR CHEMICAL AND CHEMO-ENZYMATIC SYNTHESIS OF COMPLEX GLYCANS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2012-10-04 WO disclosed
US-20120142560-A1 HEPARAN SULFATE SYNTHESIS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2012-06-07 US disclosed
EP-2414371-A2 HEPARAN SULFATE SYNTHESIS The University Of Georgia Research Foundation, Inc (US) 2012-02-08 EP disclosed
US-20110053902-A1 AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2011-03-03 US disclosed
WO-2010117803-A2 HEPARAN SULFATE SYNTHESIS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2010-10-14 WO disclosed
CN-1239112-A Light-resistant flame-retardant styrene resin composition QIMEI IND CO LTD (CN) 1999-12-22 CN disclosed
EP-0923539-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-06-23 EP disclosed
WO-1998003473-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-01-29 WO disclosed